Boult Wade Tennant
People » Dr Nadia Tyler-Rubinstein

Dr Nadia Tyler-Rubinstein

Partner

London

Contact
Download V-card
Address
Memberships
  • CIPA
  • EPI
Qualifications
  • Registered UPC Representative
  • European Patent Attorney
  • Chartered Patent Attorney
  • Certificate in Intellectual Property Law, Queen Mary University of London
  • PhD Clinical Sciences Metabolism and Disease, Imperial College London
  • BSc (Hons) Molecular Biology with Industrial Experience, University of Manchester

As a Partner at Boult I work with a range of clients including individual inventors, new start-ups as well as commercial-stage companies.

I have a PhD in metabolism and diabetes, although my practice focuses on a variety of biotechnology disciplines including antibody therapeutics, regenerative medicine, cell culture methods, cancer diagnostics, biomarkers, and targeted protein degradation.

I am able to guide clients through all stages of the patent process and have experience in drafting and prosecution, managing global patent portfolios, patent filing strategies for example to protect pre-clinical and clinical stage biologics, competitor monitoring, freedom-to-operate, opposition and appeal proceedings before the EPO, and infringement and validity assessments. I am also proficient in the filing of Supplementary Protection Certificates (SPCs) and paediatric extensions.

I have a particular interest in the interplay between IP rights and regulatory exclusivity, so I can provide practical advice for my clients that are navigating marketing authorisations, regulatory requirements, loss of exclusivity and biosimilar entry. This requires that I stay on top of changes in relevant government policy and pharmaceutical legislation both in the UK and Europe.

I remain engaged in other aspects of the life sciences industry having previously assisted as an editor for an online science and technology journal. I also write articles regularly on key topics of interest.

Boult was always my first choice of firm, and I joined here initially as a patent trainee. We hire individuals with strong academic backgrounds and place a real emphasis on high quality training. There is a wealth of talent here.

Recent experience

Coordinating the filing of a portfolio of SPC applications for various biopharmaceutical companies, ensuring their lead therapeutics receive robust protection in Europe.

Leading an opposition and subsequent appeal before the EPO resulting in a successful result for our client, a global healthcare company, and revocation of their competitor’s patent.

Successfully defending an important patent for our client relating to stem cell therapies during opposition proceedings.

Publications
Relevant Search Terms
Recommended Sites
  • https://ipkitten.blogspot.com/
  • https://royalsociety.org/
  • https://www.ema.europa.eu/en
  • https://www.gov.uk/government/organisations/-medicines-and-healthcare-products-regulatory-agency
  • https://www.bio.org/events/bio-international-convention
  • https://www.bioindustry.org/
Suggested Media
  • As mentioned previously
Recognitions
Additional Info
Languages
“I particularly enjoy managing a client’s global portfolio and formulating strategies to obtain the best possible protection for their ideas despite varying practices around the world.”
Sector experience
Biotechnology
  • Antibody engineering
  • Antibody manufacture and formulation
  • Drug delivery
  • Gene editing (e.g. CRISPR)
  • Genomic and molecular tools and methods
  • Immuno-oncology (e.g. checkpoint inhibitors; modified T cells)
  • Next generation sequencing
  • Nucleic acid synthesis
  • Personalised medicine/disease biomarkers
  • Recombinant protein production and purification
  • Stem cell therapies
  • Supplementary protection certificates (SPCs)
  • Synthetic biology
  • Therapeutic antibodies
Medical Devices and Diagnostics
  • Drug delivery
  • In vitro diagnostics

As a Partner at Boult I work with a range of clients including individual inventors, new start-ups as well as commercial-stage companies.

I have a PhD in metabolism and diabetes, although my practice focuses on a variety of biotechnology disciplines including antibody therapeutics, regenerative medicine, cell culture methods, cancer diagnostics, biomarkers, and targeted protein degradation.

I am able to guide clients through all stages of the patent process and have experience in drafting and prosecution, managing global patent portfolios, patent filing strategies for example to protect pre-clinical and clinical stage biologics, competitor monitoring, freedom-to-operate, opposition and appeal proceedings before the EPO, and infringement and validity assessments. I am also proficient in the filing of Supplementary Protection Certificates (SPCs) and paediatric extensions.

I have a particular interest in the interplay between IP rights and regulatory exclusivity, so I can provide practical advice for my clients that are navigating marketing authorisations, regulatory requirements, loss of exclusivity and biosimilar entry. This requires that I stay on top of changes in relevant government policy and pharmaceutical legislation both in the UK and Europe.

I remain engaged in other aspects of the life sciences industry having previously assisted as an editor for an online science and technology journal. I also write articles regularly on key topics of interest.

Boult was always my first choice of firm, and I joined here initially as a patent trainee. We hire individuals with strong academic backgrounds and place a real emphasis on high quality training. There is a wealth of talent here.

Recent experience

Coordinating the filing of a portfolio of SPC applications for various biopharmaceutical companies, ensuring their lead therapeutics receive robust protection in Europe.

Leading an opposition and subsequent appeal before the EPO resulting in a successful result for our client, a global healthcare company, and revocation of their competitor’s patent.

Successfully defending an important patent for our client relating to stem cell therapies during opposition proceedings.

Publications
Relevant Search Terms
Recommended Sites
  • https://ipkitten.blogspot.com/
  • https://royalsociety.org/
  • https://www.ema.europa.eu/en
  • https://www.gov.uk/government/organisations/-medicines-and-healthcare-products-regulatory-agency
  • https://www.bio.org/events/bio-international-convention
  • https://www.bioindustry.org/
Suggested Media
  • As mentioned previously
Recognitions
Additional Info

Insights

Guide to IP rights and exclusivity for pharma and biotech in Europe

Discover how patent protection plays a fundamental role in incentivising and rewarding research and development in the pharmaceutical and biotechnology sectors. Click

An IP guide to Biosimilars

Overview of EMA-defined biosimilars, EU IP protections and limits including Bolar exemption, SPC manufacturing waiver, skinny labelling and loss of exclusivity strategies.

Trends in therapeutic innovation

We reflect on a year of life sciences innovation, highlighting Clarivate’s Drugs to Watch 2025, emerging therapy trends, AI-driven R&D and the evolving patent strategies shaping the sector.

CJEU decision concerning SPCs for combination products (joined cases C-119/22 and C-149/22)

The CJEU clarifies SPC Regulation Article 3, ruling on combination products and basic patent protection, aligning with the AG’s opinion but leaving interpretation of "invention" under Article 3(a) open.

Update: Oral proceedings in case G1/24 – we await the Enlarged Board’s written decision

Oral proceedings before the Enlarged Board of Appeal (G1/24) were held on 28 March 2025, to discuss the extent to which the

When can an SPC be granted for combination medicinal products?

Opinion of the Advocate General regarding joined cases Teva II (C-119/22) and MSD (C-149/22) Two referrals have been made to the Court

INSIGHTS